166 related articles for article (PubMed ID: 37046036)
1. Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer.
Sakamoto A; Inoue H; Miyamoto S; Ito S; Soda Y; Tani K
Sci Rep; 2023 Apr; 13(1):5924. PubMed ID: 37046036
[TBL] [Abstract][Full Text] [Related]
2. Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma.
Okamura K; Inoue H; Tanaka K; Ikematsu Y; Furukawa R; Ota K; Yoneshima Y; Iwama E; Okamoto I
Cancer Sci; 2023 Mar; 114(3):1095-1107. PubMed ID: 36369966
[TBL] [Abstract][Full Text] [Related]
3. A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11.
Wang B; Ogata H; Takishima Y; Miyamoto S; Inoue H; Kuroda M; Yamada K; Hijikata Y; Murahashi M; Shimizu H; Okazaki T; Nakanishi Y; Tani K
Anticancer Res; 2018 Nov; 38(11):6121-6126. PubMed ID: 30396927
[TBL] [Abstract][Full Text] [Related]
4. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.
Miyamoto S; Inoue H; Nakamura T; Yamada M; Sakamoto C; Urata Y; Okazaki T; Marumoto T; Takahashi A; Takayama K; Nakanishi Y; Shimizu H; Tani K
Cancer Res; 2012 May; 72(10):2609-21. PubMed ID: 22461509
[TBL] [Abstract][Full Text] [Related]
5. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.
Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763
[TBL] [Abstract][Full Text] [Related]
6. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
7. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
Relph K; Annels N; Smith C; Kostalas M; Pandha H
Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
[TBL] [Abstract][Full Text] [Related]
10. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG
Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells.
Takasu A; Masui A; Hamada M; Imai T; Iwai S; Yura Y
Cancer Gene Ther; 2016 Apr; 23(4):107-13. PubMed ID: 26987291
[TBL] [Abstract][Full Text] [Related]
14. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
15. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo.
Zhang JF; Wei F; Wang HP; Li HM; Qiu W; Ren PK; Chen XF; Huang Q
J Exp Clin Cancer Res; 2010 May; 29(1):52. PubMed ID: 20487549
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.
Passaro C; Volpe M; Botta G; Scamardella E; Perruolo G; Gillespie D; Libertini S; Portella G
Mol Oncol; 2015 Jan; 9(1):78-92. PubMed ID: 25139258
[TBL] [Abstract][Full Text] [Related]
17. [Synergistic Effect of NF-κB Signaling Pathway Inhibitor and Oncolytic
Measles Virus Vaccine Strain against Lung Cancer and Underlying Mechanisms].
Xia M; Meng G; Dong J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):245-253. PubMed ID: 33775041
[TBL] [Abstract][Full Text] [Related]
18. Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
Sagara M; Miyamoto S; Itoh S; Soda Y; Tani K
Anticancer Res; 2021 Jan; 41(1):81-89. PubMed ID: 33419801
[TBL] [Abstract][Full Text] [Related]
19. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.
Hazini A; Pryshliak M; Brückner V; Klingel K; Sauter M; Pinkert S; Kurreck J; Fechner H
Hum Gene Ther; 2018 Nov; 29(11):1301-1314. PubMed ID: 29739251
[TBL] [Abstract][Full Text] [Related]
20. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
